Association of COVID‐19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis
Abstract Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)‐associated vasculitis (AAV). Although quite rare, AAV may occur with SARS‐coronavirus disease 2019 (COVID‐19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID‐19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID‐19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Respirology Case Reports - 10(2022), 1, Seite n/a-n/a |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jamie R. Felzer [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Diseases of the respiratory system |
---|
doi: |
10.1002/rcr2.894 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ00742938X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ00742938X | ||
003 | DE-627 | ||
005 | 20230503103923.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/rcr2.894 |2 doi | |
035 | |a (DE-627)DOAJ00742938X | ||
035 | |a (DE-599)DOAJc30b3d63a27e42db9dcb60d75783e8fc | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC705-779 | |
100 | 0 | |a Jamie R. Felzer |e verfasserin |4 aut | |
245 | 1 | 0 | |a Association of COVID‐19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)‐associated vasculitis (AAV). Although quite rare, AAV may occur with SARS‐coronavirus disease 2019 (COVID‐19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID‐19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID‐19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes. | ||
650 | 4 | |a granulomatosis with polyangiitis | |
650 | 4 | |a haemoptysis | |
650 | 4 | |a respiratory failure | |
650 | 4 | |a vasculitis | |
653 | 0 | |a Diseases of the respiratory system | |
700 | 0 | |a Delvise T. Fogwe |e verfasserin |4 aut | |
700 | 0 | |a Shaher Samrah |e verfasserin |4 aut | |
700 | 0 | |a Clement J. Michet Jr |e verfasserin |4 aut | |
700 | 0 | |a Ulrich Specks |e verfasserin |4 aut | |
700 | 0 | |a Misbah Baqir |e verfasserin |4 aut | |
700 | 0 | |a Aahd F. Kubbara |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Respirology Case Reports |d Wiley, 2015 |g 10(2022), 1, Seite n/a-n/a |w (DE-627)DOAJ000057134 |x 20513380 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2022 |g number:1 |g pages:n/a-n/a |
856 | 4 | 0 | |u https://doi.org/10.1002/rcr2.894 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/c30b3d63a27e42db9dcb60d75783e8fc |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1002/rcr2.894 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2051-3380 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 10 |j 2022 |e 1 |h n/a-n/a |